{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:00:56Z","timestamp":1793883656093,"version":"4.7.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1038\/s41591-025-04189-2","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T10:06:09Z","timestamp":1769594769000},"page":"1316-1324","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial"],"prefix":"10.1038","volume":"32","author":[{"given":"Serena","family":"Porcari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Ciccarese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6617-9187","authenticated-orcid":false,"given":"Vitor","family":"Heidrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora","family":"Rondinella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Quaranta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Severino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Arduini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0876-0226","authenticated-orcid":false,"given":"Sebastiano","family":"Buti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4754-6572","authenticated-orcid":false,"given":"Giuseppe","family":"Fornarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Primi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2424-4390","authenticated-orcid":false,"given":"Luciano","family":"Stumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Giannarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia Claire","family":"Giudice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Damassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio Rodrigo","family":"Giron Berr\u00edos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1915-9391","authenticated-orcid":false,"given":"Michal","family":"Pun\u010doch\u00e1\u0159","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas B.","family":"Barbazuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1947-1817","authenticated-orcid":false,"given":"Gianmarco","family":"Piccinno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4539-4811","authenticated-orcid":false,"given":"Federica","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Armanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3732-1468","authenticated-orcid":false,"given":"Francesco","family":"Asnicar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Schinzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Derosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9334-4405","authenticated-orcid":false,"given":"Guido","family":"Kroemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9780-7059","authenticated-orcid":false,"given":"Maurizio","family":"Sanguinetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8358-6726","authenticated-orcid":false,"given":"Luca","family":"Masucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gasbarrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Tortora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3626-6148","authenticated-orcid":false,"given":"Giovanni","family":"Cammarota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1596-0998","authenticated-orcid":false,"given":"Laurence","family":"Zitvogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1583-5794","authenticated-orcid":false,"given":"Nicola","family":"Segata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Iacovelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8318-0515","authenticated-orcid":false,"given":"Gianluca","family":"Ianiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"4189_CR1","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini, B. I. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1116\u20131127 (2019).","journal-title":"N. Engl. J. Med."},{"key":"4189_CR2","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41591-024-02823-z","volume":"30","author":"A Gunjur","year":"2024","unstructured":"Gunjur, A. et al. A gut microbial signature for combination immune checkpoint blockade across cancer types. Nat. Med. 30, 797\u2013809 (2024).","journal-title":"Nat. Med."},{"key":"4189_CR3","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1136\/gutjnl-2016-312297","volume":"65","author":"G Ianiro","year":"2016","unstructured":"Ianiro, G. et al. Antibiotics as deep modulators of gut microbiota: between good and evil. Gut 65, 1906\u20131915 (2016).","journal-title":"Gut"},{"key":"4189_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1075593","volume":"13","author":"A Crespin","year":"2023","unstructured":"Crespin, A. et al. A systematic review and meta-analysis evaluating the impact of antibiotic use on the clinical outcomes of cancer patients treated with immune checkpoint inhibitors. Front. Oncol. 13, 1075593 (2023).","journal-title":"Front. Oncol."},{"key":"4189_CR5","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/annonc\/mdy103","volume":"29","author":"L Derosa","year":"2018","unstructured":"Derosa, L. et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann. Oncol. 29, 1437\u20131444 (2018).","journal-title":"Ann. Oncol."},{"key":"4189_CR6","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.aad1329","volume":"350","author":"M V\u00e9tizou","year":"2015","unstructured":"V\u00e9tizou, M. et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350, 1079\u20131084 (2015).","journal-title":"Science"},{"key":"4189_CR7","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1126\/science.abb5920","volume":"371","author":"EN Baruch","year":"2021","unstructured":"Baruch, E. N. et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science 371, 602\u2013609 (2021).","journal-title":"Science"},{"key":"4189_CR8","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1126\/science.abf3363","volume":"371","author":"D Davar","year":"2021","unstructured":"Davar, D. et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science 371, 595\u2013602 (2021).","journal-title":"Science"},{"key":"4189_CR9","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.chom.2024.06.010","volume":"32","author":"Y Kim","year":"2024","unstructured":"Kim, Y. et al. Fecal microbiota transplantation improves anti-PD-1 inhibitor efficacy in unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor. Cell Host Microbe 32, 1380\u20131393 (2024).","journal-title":"Cell Host Microbe"},{"key":"4189_CR10","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1038\/s41591-023-02453-x","volume":"29","author":"B Routy","year":"2023","unstructured":"Routy, B. et al. Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial. Nat. Med. 29, 2121\u20132132 (2023).","journal-title":"Nat. Med."},{"key":"4189_CR11","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.65088","volume":"10","author":"F Beghini","year":"2021","unstructured":"Beghini, F. et al. Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery 3. eLife 10, e65088 (2021).","journal-title":"eLife"},{"key":"4189_CR12","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1038\/s41587-023-01688-w","volume":"41","author":"A Blanco-M\u00edguez","year":"2023","unstructured":"Blanco-M\u00edguez, A. et al. Extending and improving metagenomic taxonomic profiling with uncharacterized species using MetaPhlAn 4. Nat. Biotechnol. 41, 1633\u20131644 (2023).","journal-title":"Nat. Biotechnol."},{"key":"4189_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.20517\/mrr.2024.28","volume":"3","author":"R Kumar","year":"2024","unstructured":"Kumar, R. et al. Akkermansia beyond muciniphila\u2014emergence of new species Akkermansia massiliensis sp. nov. Microbiome Res. Rep. 3, 37 (2024).","journal-title":"Microbiome Res. Rep."},{"key":"4189_CR14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.20517\/mrr.2024.09","volume":"3","author":"KD Mueller","year":"2024","unstructured":"Mueller, K. D. et al. Pangenomic analysis identifies correlations between Akkermansia species and subspecies and human health outcomes. Microbiome Res. Rep. 3, 33 (2024).","journal-title":"Microbiome Res. Rep."},{"key":"4189_CR15","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/apt.13144","volume":"41","author":"G Cammarota","year":"2015","unstructured":"Cammarota, G. et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment. Pharmacol. Ther. 41, 835\u2013843 (2015).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"4189_CR16","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/apt.14816","volume":"48","author":"G Ianiro","year":"2018","unstructured":"Ianiro, G. et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection\u2014single versus multiple infusions. Aliment. Pharmacol. Ther. 48, 152\u2013159 (2018).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"4189_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18127-y","volume":"11","author":"G Ianiro","year":"2020","unstructured":"Ianiro, G. et al. Faecal microbiota transplantation for the treatment of diarrhoea induced by tyrosine-kinase inhibitors in patients with metastatic renal cell carcinoma. Nat. Commun. 11, 4333 (2020).","journal-title":"Nat. Commun."},{"key":"4189_CR18","doi-asserted-by":"publisher","first-page":"695","DOI":"10.7326\/M18-3635","volume":"171","author":"G Ianiro","year":"2019","unstructured":"Ianiro, G. et al. Incidence of bloodstream infections, length of hospital stay, and survival in patients with recurrent Clostridioides difficile infection treated with fecal microbiota transplantation or antibiotics: a prospective cohort study. Ann. Intern. Med. 171, 695\u2013702 (2019).","journal-title":"Ann. Intern. Med."},{"key":"4189_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2023.103033","volume":"141","author":"S Porcari","year":"2023","unstructured":"Porcari, S. et al. Fecal microbiota transplantation for recurrent Clostridioides difficile infection in patients with concurrent ulcerative colitis. J. Autoimmun. 141, 103033 (2023).","journal-title":"J. Autoimmun."},{"key":"4189_CR20","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/S1473-3099(19)30545-6","volume":"19","author":"EJ Kuijper","year":"2019","unstructured":"Kuijper, E. J. et al. A necessary discussion after transmission of multidrug-resistant organisms through faecal microbiota transplantations. Lancet Infect. Dis. 19, 1161\u20131162 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"4189_CR21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/apt.16148","volume":"53","author":"C Marcella","year":"2021","unstructured":"Marcella, C. et al. Systematic review: the global incidence of faecal microbiota transplantation-related adverse events from 2000 to 2020. Aliment. Pharmacol. Ther. 53, 33\u201342 (2021).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"4189_CR22","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3390\/metabo15060412","volume":"15","author":"I Domilescu","year":"2025","unstructured":"Domilescu, I. et al. Gut-microbiome signatures predicting response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review. Metabolites 15, 412 (2025).","journal-title":"Metabolites"},{"key":"4189_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32015-7","volume":"13","author":"K Hosomi","year":"2022","unstructured":"Hosomi, K. et al. Oral administration of Blautia wexlerae ameliorates obesity and type 2 diabetes via metabolic remodeling of the gut microbiota. Nat. Commun. 13, 4477 (2022).","journal-title":"Nat. Commun."},{"key":"4189_CR24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41591-021-01655-5","volume":"28","author":"L Derosa","year":"2022","unstructured":"Derosa, L. et al. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nat. Med. 28, 315\u2013324 (2022).","journal-title":"Nat. Med."},{"key":"4189_CR25","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1016\/j.cell.2024.05.029","volume":"187","author":"L Derosa","year":"2024","unstructured":"Derosa, L. et al. Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome. Cell 187, 3373\u20133389 (2024).","journal-title":"Cell"},{"key":"4189_CR26","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41591-022-01695-5","volume":"28","author":"KA Lee","year":"2022","unstructured":"Lee, K. A. et al. Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma. Nat. Med. 28, 535\u2013544 (2022).","journal-title":"Nat. Med."},{"key":"4189_CR27","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2025.2484880","volume":"14","author":"R Birebent","year":"2025","unstructured":"Birebent, R. et al. Surrogate markers of intestinal dysfunction associated with survival in advanced cancers. Oncoimmunology 14, 2484880 (2025).","journal-title":"Oncoimmunology"},{"key":"4189_CR28","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1038\/s41396-022-01227-6","volume":"16","author":"RR Segura Munoz","year":"2022","unstructured":"Segura Munoz, R. R. et al. Correction: Experimental evaluation of ecological principles to understand and modulate the outcome of bacterial strain competition in gut microbiomes. ISME J. 16, 1681\u20131682 (2022).","journal-title":"ISME J."},{"key":"4189_CR29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nrmicro818","volume":"2","author":"JB Kaper","year":"2004","unstructured":"Kaper, J. B. et al. Pathogenic Escherichia coli. Nat. Rev. Microbiol. 2, 123\u2013140 (2004).","journal-title":"Nat. Rev. Microbiol."},{"key":"4189_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.115018","volume":"43","author":"V Valentino","year":"2024","unstructured":"Valentino, V. et al. Genomic features and prevalence of Ruminococcus species in humans are associated with age, lifestyle, and disease. Cell Rep. 43, 115018 (2024).","journal-title":"Cell Rep."},{"key":"4189_CR31","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1038\/s41591-022-01964-3","volume":"28","author":"G Ianiro","year":"2022","unstructured":"Ianiro, G. et al. Variability of strain engraftment and predictability of microbiome composition after fecal microbiota transplantation across different diseases. Nat. Med. 28, 1913\u20131923 (2022).","journal-title":"Nat. Med."},{"key":"4189_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2024.105341","volume":"26","author":"D Rondinella","year":"2024","unstructured":"Rondinella, D. et al. Donor screening for fecal microbiota transplantation with a direct stool testing-based strategy: a prospective cohort study. Microbes Infect. 26, 105341 (2024).","journal-title":"Microbes Infect."},{"key":"4189_CR33","doi-asserted-by":"publisher","first-page":"100181","DOI":"10.1016\/j.lanepe.2021.100181","volume":"9","author":"SMD Baunwall","year":"2021","unstructured":"Baunwall, S. M. D. et al. The use of faecal microbiota transplantation (FMT) in Europe: a Europe-wide survey. Lancet Reg. Health Eur. 9, 100181 (2021).","journal-title":"Lancet Reg. Health Eur."},{"key":"4189_CR34","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1038\/s41591-024-03086-4","volume":"30","author":"H Ebrahimi","year":"2024","unstructured":"Ebrahimi, H. et al. Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nat. Med. 30, 2576\u20132585 (2024).","journal-title":"Nat. Med."},{"key":"4189_CR35","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/s41591-022-01694-6","volume":"28","author":"N Dizman","year":"2022","unstructured":"Dizman, N. et al. Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nat. Med. 28, 704\u2013712 (2022).","journal-title":"Nat. Med."},{"key":"4189_CR36","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.annonc.2023.02.011","volume":"34","author":"A Spreafico","year":"2023","unstructured":"Spreafico, A. et al. First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial). Ann. Oncol. 34, 520\u2013530 (2023).","journal-title":"Ann. Oncol."},{"key":"4189_CR37","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1038\/s41591-025-03635-5","volume":"31","author":"S Hopewell","year":"2025","unstructured":"Hopewell, S. et al. CONSORT 2025 statement: updated guideline for reporting randomized trials. Nat. Med. 31, 1776\u20131783 (2025).","journal-title":"Nat. Med."},{"key":"4189_CR38","doi-asserted-by":"publisher","first-page":"2525478","DOI":"10.1080\/19490976.2025.2525478","volume":"17","author":"C Herman","year":"2025","unstructured":"Herman, C. et al. Assessing engraftment following fecal microbiota transplant. Gut Microbes 17, 2525478 (2025).","journal-title":"Gut Microbes"},{"key":"4189_CR39","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"4189_CR40","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1136\/gutjnl-2019-319548","volume":"68","author":"G Cammarota","year":"2019","unstructured":"Cammarota, G. et al. International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. Gut 68, 2111\u20132121 (2019).","journal-title":"Gut"},{"key":"4189_CR41","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1136\/gutjnl-2020-321829","volume":"69","author":"G Ianiro","year":"2020","unstructured":"Ianiro, G. et al. Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic. Gut 69, 1555\u20131563 (2020).","journal-title":"Gut"},{"key":"4189_CR42","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1177\/2050640618780762","volume":"6","author":"G Ianiro","year":"2018","unstructured":"Ianiro, G. et al. Efficacy of different faecal microbiota transplantation protocols for Clostridium difficile infection: a systematic review and meta-analysis. United European Gastroenterol. J. 6, 1232\u20131244 (2018).","journal-title":"United European Gastroenterol. J."},{"key":"4189_CR43","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/jam.14522","volume":"128","author":"G Quaranta","year":"2020","unstructured":"Quaranta, G. et al. Laboratory handling practice for faecal microbiota transplantation. J. Appl. Microbiol. 128, 893\u2013898 (2020).","journal-title":"J. Appl. Microbiol."},{"key":"4189_CR44","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1001\/jama.2017.17077","volume":"318","author":"D Kao","year":"2017","unstructured":"Kao, D. et al. Effect of oral capsule vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection: a randomized clinical trial. JAMA 318, 1985\u20131993 (2017).","journal-title":"JAMA"},{"key":"4189_CR45","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1007\/s10620-018-5396-6","volume":"64","author":"JR Allegretti","year":"2019","unstructured":"Allegretti, J. R. et al. Fecal microbiota transplantation capsules with targeted colonic versus gastric delivery in recurrent Clostridium difficile infection: a comparative cohort analysis of high and low dose. Dig. Dis. Sci. 64, 1672\u20131678 (2019).","journal-title":"Dig. Dis. Sci."},{"key":"4189_CR46","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41586-022-05620-1","volume":"614","author":"M Valles-Colomer","year":"2023","unstructured":"Valles-Colomer, M. et al. The person-to-person transmission landscape of the gut and oral microbiomes. Nature 614, 125\u2013135 (2023).","journal-title":"Nature"},{"key":"4189_CR47","doi-asserted-by":"publisher","first-page":"3942","DOI":"10.1016\/j.cell.2025.04.014","volume":"188","author":"S Andreu-S\u00e1nchez","year":"2025","unstructured":"Andreu-S\u00e1nchez, S. et al. Global genetic diversity of human gut microbiome species is related to geographic location and host health. Cell 188, 3942\u20133959 (2025).","journal-title":"Cell"},{"key":"4189_CR48","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nbt.2939","volume":"32","author":"HB Nielsen","year":"2014","unstructured":"Nielsen, H. B. et al. Identification and assembly of genomes and genetic elements in complex metagenomic samples without using reference genomes. Nat. Biotechnol. 32, 822\u2013828 (2014).","journal-title":"Nat. Biotechnol."},{"key":"4189_CR49","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.chom.2015.01.001","volume":"17","author":"AD Kostic","year":"2015","unstructured":"Kostic, A. D. et al. The dynamics of the human infant gut microbiome in development and in progression toward type 1 diabetes. Cell Host Microbe 17, 260\u2013273 (2015).","journal-title":"Cell Host Microbe"},{"key":"4189_CR50","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.chom.2015.04.004","volume":"17","author":"F B\u00e4ckhed","year":"2015","unstructured":"B\u00e4ckhed, F. et al. Dynamics and stabilization of the human gut microbiome during the first year of life. Cell Host Microbe 17, 690\u2013703 (2015).","journal-title":"Cell Host Microbe"},{"key":"4189_CR51","doi-asserted-by":"publisher","first-page":"e0149564","DOI":"10.1371\/journal.pone.0149564","volume":"11","author":"S Louis","year":"2016","unstructured":"Louis, S. et al. Characterization of the gut microbial community of obese patients following a weight-loss intervention using whole metagenome shotgun sequencing. PLoS ONE 11, e0149564 (2016).","journal-title":"PLoS ONE"},{"key":"4189_CR52","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.cell.2016.04.007","volume":"165","author":"T Vatanen","year":"2016","unstructured":"Vatanen, T. et al. Variation in microbiome LPS immunogenicity contributes to autoimmunity in humans. Cell 165, 842\u2013853 (2016).","journal-title":"Cell"},{"key":"4189_CR53","doi-asserted-by":"publisher","first-page":"16180","DOI":"10.1038\/nmicrobiol.2016.180","volume":"2","author":"A Heintz-Buschart","year":"2016","unstructured":"Heintz-Buschart, A. et al. Integrated multi-omics of the human gut microbiome in a case study of familial type 1 diabetes. Nat. Microbiol. 2, 16180 (2016).","journal-title":"Nat. Microbiol."},{"key":"4189_CR54","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/nm.4272","volume":"23","author":"DM Chu","year":"2017","unstructured":"Chu, D. M. et al. Maturation of the infant microbiome community structure and function across multiple body sites and in relation to mode of delivery. Nat. Med. 23, 314\u2013326 (2017).","journal-title":"Nat. Med."},{"key":"4189_CR55","doi-asserted-by":"publisher","first-page":"e00164","DOI":"10.1128\/mSystems.00164-16","volume":"2","author":"F Asnicar","year":"2017","unstructured":"Asnicar, F. et al. Studying vertical microbiome transmission from mothers to infants by strain-level metagenomic profiling. mSystems 2, e00164\u201316 (2017).","journal-title":"mSystems"},{"key":"4189_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-017-0490-5","volume":"9","author":"AB Hall","year":"2017","unstructured":"Hall, A. B. et al. A novel Ruminococcus gnavus clade enriched in inflammatory bowel disease patients. Genome Med. 9, 103 (2017).","journal-title":"Genome Med."},{"key":"4189_CR57","doi-asserted-by":"publisher","first-page":"960","DOI":"10.15252\/msb.20177589","volume":"13","author":"PI Costea","year":"2017","unstructured":"Costea, P. I. et al. Subspecies in the global human gut microbiome. Mol. Syst. Biol. 13, 960 (2017).","journal-title":"Mol. Syst. Biol."},{"key":"4189_CR58","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/s41564-017-0089-z","volume":"3","author":"M Schirmer","year":"2018","unstructured":"Schirmer, M. et al. Dynamics of metatranscription in the inflammatory bowel disease gut microbiome. Nat. Microbiol. 3, 337\u2013346 (2018).","journal-title":"Nat. Microbiol."},{"key":"4189_CR59","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41564-017-0096-0","volume":"3","author":"RS Mehta","year":"2018","unstructured":"Mehta, R. S. et al. Stability of the human faecal microbiome in a cohort of adult men. Nat. Microbiol. 3, 347\u2013355 (2018).","journal-title":"Nat. Microbiol."},{"key":"4189_CR60","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.chom.2018.06.005","volume":"24","author":"P Ferretti","year":"2018","unstructured":"Ferretti, P. et al. Mother-to-infant microbial transmission from different body sites shapes the developing infant gut microbiome. Cell Host Microbe 24, 133\u2013145 (2018).","journal-title":"Cell Host Microbe"},{"key":"4189_CR61","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.chom.2018.06.007","volume":"24","author":"M Yassour","year":"2018","unstructured":"Yassour, M. et al. Strain-level analysis of mother-to-child bacterial transmission during the first few months of life. Cell Host Microbe 24, 146\u2013154 (2018).","journal-title":"Cell Host Microbe"},{"key":"4189_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07631-x","volume":"9","author":"L Wampach","year":"2018","unstructured":"Wampach, L. et al. Birth mode is associated with earliest strain-conferred gut microbiome functions and immunostimulatory potential. Nat. Commun. 9, 5091 (2018).","journal-title":"Nat. Commun."},{"key":"4189_CR63","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41586-019-1237-9","volume":"569","author":"J Lloyd-Price","year":"2019","unstructured":"Lloyd-Price, J. et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature 569, 655\u2013662 (2019).","journal-title":"Nature"},{"key":"4189_CR64","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41586-019-1560-1","volume":"574","author":"Y Shao","year":"2019","unstructured":"Shao, Y. et al. Stunted microbiota and opportunistic pathogen colonization in caesarean-section birth. Nature 574, 117\u2013121 (2019).","journal-title":"Nature"},{"key":"4189_CR65","first-page":"32","volume":"26","author":"MJ Anderson","year":"2001","unstructured":"Anderson, M. J. A new method for non-parametric multivariate analysis of variance. Austral Ecol. 26, 32\u201346 (2001).","journal-title":"Austral Ecol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04189-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04189-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04189-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T14:02:10Z","timestamp":1776780130000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04189-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4189"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-04189-2","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"27 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.P. has served as a speaker for WellMicro. G.K. has been holding research contracts with Daiichi-Sankyo, Eleor, Kaleido, Lytix Pharma, PharmaMar, Osasuna Therapeutics, Samsara Therapeutics, Sanofi, Sutro, Tollys and Vascage. G.K. is on the Board of Directors of Bristol Myers Squibb Foundation France. G.K. is also a scientific co-founder of everImmune, Osasuna Therapeutics, Samsara Therapeutics and Therafast Bio; is on the scientific advisory boards of Hevolution, Institut Servier and Rejuveron Life Sciences\/Centenara Labs AG; and is the inventor of patents covering therapeutic targeting of aging, cancer, cystic fibrosis and metabolic disorders. A close family member of G.K. was an employee of Sanofi and now consults for Boehringer Ingelheim. A.G. reports personal fees for consultancy for Eisai S.r.l., 3PSolutions, Real Time Meeting, Fondazione Istituto Danone, Sinergie S.r.l. Board MRGE and Sanofi S.p.A.; personal fees for acting as a speaker for Takeda S.p.A., AbbVie and Sandoz S.p.A.; and personal fees for acting on advisory boards for VSL3 and Eisai. L.Z. is a co-founder of everImmune and its scientific advisory board president; received a research contract from Kaleido and 9 Meters\/Innovate Pharma; and is sponsored by Pileje. G.C. has received personal fees for acting as an advisor for Ferring Therapeutics. G.I. has received personal fees for acting as a speaker for Biocodex and Illumina and for acting as a consultant\/advisor for Ferring Therapeutics. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}